Advice
Following a full submission
fondaparinux sodium (Arixtra®) is accepted for use within NHS Scotland for the treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.
Fondaparinux significantly reduced mortality and reinfarction during the 30 days following onset of symptoms compared to placebo and was not associated with an increased risk of bleeding.
Download detailed advice55KB (PDF)
Medicine details
- Medicine name:
- fondiparinux sodium (Arixtra)
- SMC ID:
- 439/08
- Indication:
- Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 February 2008